LONDON, Mar 9: An anti-inflammatory drug normally used to treat rheumatoid arthritis reduces the risk of death when given to hospitalised patients with severe COVID-19, according to a study led by researchers at the University of Oxford. The benefit of baricitinib is in addition to those of dexamethasone and tocilizumab, two other anti-inflammatory treatments which have previously been shown to reduce the risk of death in these patients, the researchers said. “It is now well-established that in people admitted to hospital […]